With advanced liver disease often being undiagnosed, early assessment of fibrosis is critical to enable timely intervention before cirrhosis1

The risks of disease progression and severe liver-related consequences increase starting with moderate fibrosis (F2)1

MASH with moderate to advanced fibrosis (F2-F3) is a progressive liver disease with severe consequences, including:

Cirrhosis
 

MASH is a leading cause of cirrhosis in the US2


22% of patients with F3 progress to cirrhosis within 2 years3

Liver Transplant
 

MASH is the leading cause of liver transplantation in women and second leading cause for all liver transplantation in the US4,5

Hepatocellular Carcinoma (HCC)

~3x increased risk of HCC for patients with noncirrhotic MASH with fibrosis vs those with liver disease of other etiologies6

Mortality
 

~10-17x higher risk of liver‑related mortality for patients with F2-F3 vs F07,8

The stages of fibrosis progression9

Liver fibrosis progression from F1 to F4

Rezdiffra delivered statistically significant results for both primary endpoints in MAESTRO-NASH10

See Dual Efficacy
MASH=metabolic dysfunction-associated steatohepatitis.
References:
  1. Rinella ME et al. Hepatology. 2023;77(5):1797-1835.
  2. Tran S et al. Aliment Pharmacol Ther. 2024;60(2):212-223.
  3. Loomba R, Adams LA. Hepatology. 2019;70(6):1885-1888.
  4. Chalasani N et al. Hepatology. 2018;67(1):328357.
  5. Noureddin M et al. Am J Gastroenterol. 2018;113(11):1649-1659.
  6. Stine JG et al. Aliment Pharmacol Ther. 2018;48(7):696-703.
  7. Dulai PS et al. Hepatology. 2017;65(5):1557-1565.
  8. Angulo P et al. Gastroenterology. 2015;149(2):389-97.e10.
  9. Lomonaco R et al. Diabetes Care. 2021;44(2):399-406.
  10. Rezdiffra. Prescribing Information. Madrigal Pharmaceuticals, Inc.